
Section B: Organic, Analytical and Pharmaceutical Chemistry.

Review Article

Review of different approach for determination of Colchicine

Israa A. Wahba^{a*}

^aPharmaceutical Analytical Chemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science & Technology, 6th of October City, Giza, Egypt.

*Correspondence: esraa.adel@Must.edu.eg; Tel.: +2 01066885046

Received: 29 December 2023

Abstract

Accepted: 5 May 2024

Published: 6 May 2024

Editors

Marwa Mohanad
Mahmoud Eltahan

Keywords

Analytical approaches.
Colchicine.
Osteoarthritis.
Gout.

Colchicine is primarily used to treat gout, but it can also be used to treat other inflammatory diseases, such as familial Mediterranean fever (FMF). It was initially granted FDA approval in 2009 for the prevention of acute attacks and treatment of them, following a critical trial that demonstrated the medication's effectiveness. Excretion of colchicine and its metabolites occurs via the biliary and urine systems.

Several analytical methods used in the present literature to quantify are gathered and discussed in this systematic study which include UV-visible spectroscopy, spectrofluorimetry, electrochemical methods, and other chromatographic techniques such as HPLC, TLC and capillary electrophoresis. This work investigates the comparative application of several analytical techniques to determine colchicine. The information provided in this review study may be used to effectively carry out additional analytical research for quantitative determination of colchicine in crude drug, pharmaceutical dosage forms and biological fluids.

1-Introduction

One of the most common rheumatic conditions is gouty arthritis. Although the clinical burden of gouty arthritis has long been known, gout is frequently misdiagnosed and mistreated [1]. The Egyptians discovered gout in 2640 B.C., and it was later named "the unwalkable disease" and the "disease of kings" [2]. Nowadays, gout is a well-defined rheumatologic condition that is linked to more than just lifestyle choices. A variety of clinical disorders associated with an excess of serum urate (uric acid) are collectively referred to as "gout." It can also present a range of clinical manifestations, not just the traditional podagra [2]. Although Colchicine is old drug, it has many new clinical uses, this attributed to the fact that it has many off-label uses like acute and recurrent pericarditis, biliary and hepatic cirrhosis, paget's disease of bone, pseudogout and idiopathic pulmonary fibrosis [3].

Colchicine (COC) (Fig.1) is chemically designed as N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzol[a]10tametr-7-yl) acetamide [4]. Colchicine inhibits the migration of leukocytes and other inflammatory cells by disrupting the tubulin polymerization process. Colchicine, corticosteroids, nonsteroidal anti-inflammatory

medications (NSAIDs), or a combination of the two drugs should be used to treat acute gouty arthritis [5]. Interstitial nephropathy and uric acid nephrolithiasis are possible in progressive illness, but they usually only happen in patients with more severe and prolonged hyperuricemia [6]. In addition, COC was effectively used in COVID-19 patients, this was attributed to the fact that it is an immunomodulatory drug [3]. It acts by inhibiting the NLRP3 inflammasome which produced by viroporin E, a component of SARS-CoV-2 that is responsible for generation of inflammatory response[7].

COC is official in the British [8] and US [9] pharmacopeias where it is determined by titrimetric and HPLC methods, respectively.

The goal of this review paper was to outline various analytical techniques for figuring out colchicine. These techniques included spectrophotometric, spectrofluorimetric, electrochemical, and chromatographic procedures.

2. chemistry [8]




Fig.1: Chemical structures of Colchicine

N-(5,6,7,9- tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol [a]heptalen-7-yl) acetamide

Molecular formula: C₂₂H₂₅NO₆

Molecular weight: 399.4 g/mol

Physical characters: odorless pale-yellow needles or powder, soluble in water, methanol, ethanol and chloroform, pKa 1.85, melting point: 142.0-150.0°C [8].

3. Analytical techniques

3.1. Official and reported analytical methods for the analysis of colchicine.

3.1.1. Official analytical method

Colchicine is determined in different pharmacopoeias (BP [8] and USP [9]) where official titrimetric method in BP [8] using acetic anhydride and toluene as a solvent then titrated against 0.1 M perchloric acid where the endpoint is determined potentiometrically.

COL was assayed in USP [9] via HPLC method, using mobile phase consisting of 0.5 M monobasic potassium phosphate and methanol then pH (5.5 ± 0.05) was adjusted using 0.5 M phosphoric acid. Determination of COL was obtained using 4.6-mm × 25-cm, packing L7 column, UV-detection at 254.0 nm and flow rate at 1.0 mL/ min.

3.1.2. Reported analytical methods.

a. Spectroscopic methods UV spectrophotometric methods

Sarg et al. [10] described a spectrophotometric method for determination of colchicine under UV light at 366 nm and checked against the colchicine marker.

Spectrofluorimetric methods

A spectrofluorimetric method was developed for determination of colchicine after binding to tubulin to enhance its fluorescence intensity by 300.0 -fold at 430.0 nm. This method did not necessitate the separation of the tubulin-colchicine complex from free colchicine [11].

A spectrofluorimetric method was also described for determination of colchicine in pharmaceutical preparation. The excitation and emission maxima for colchicine in distilled water were 350.0 and 399.0 nm, respectively [12].

b. Electrochemical methods

A voltametric method used to determine colchicine in human urine was developed. Remarkable peak current enhancement showed that acetylene black-dihexadecyl hydrogen phosphate modified coated glassy carbon electrode had great potential in the sensitive determination of colchicine. Good linear relationship was obtained in the range of 1.0×10^{-7} – 4.0×10^{-5} mol/L [13].

Bodoki et al. [14] investigated the electrochemical behavior of colchicine by using graphite-based screen-printed electrodes where the anodic differential pulse voltametric method in H₃PO₄/HClO₄ 0.01 M (pH= 2.05) was selected for quantitative determination of colchicine oxidation peaks at +970 mV versus Ag pseudo-reference over concentration range 85.0–1200.0 ng/ mL.

Electrochemical method was developed for the determination of colchicine in 0.1 M phosphate buffer solution (pH 4.0) upon using differential pulse voltammetry where 1-butyl-3-methylimidazolium tetrachloroferrate was synthesized. This method was developed for quantification of colchicine in commercial pharmaceutical formulations and human plasm [15].

c. Chromatographic methods

Thin Layer chromatography

A validated HPTLC method for determination of colchicine was described. The HPTLC separation was accomplished on an aluminum-backed layer of silica gel GF₂₅₄ using chloroform: methanol (95.0: 5.0, v/v) as a mobile phase. Quantitation was achieved with UV detection at 243.0 nm [10].

Bodoki et al. [16] developed a TLC method for quantitative analysis of colchicine using chloroform: acetone: di-ethylamine (5.0: 4.0 :1.0, by volume) as a mobile phase. The densitometric measurements were carried out at 350.0 nm.

High-performance thin-layer chromatographic method for concurrent analysis of colchicine and khellin was developed. The HPTLC separation was carried out on an aluminum-backed sheets of silica gel GF₂₅₄ using ethylene chloride–methanol (95.0: 5.0, v/v) as a developing system. UV detection was achieved at 245.0 nm [17].

Fahim et al. [18] investigated HP-TLC method for analysis of colchicine using toluene: dichloromethane: methanol, (10.0:10.0:10.0, by volume) as mobile phase where colchicine was detected at 350.0 nm.

High-performance thin-layer chromatography for simultaneous determination of colchicine and gallic acid was performed on pre-coated silica gel 60 GF₂₅₄ upon using ethyl acetate/acetonitrile/water/formic acid/N-dimethylformamide (7.5:1:0.5:0.5:0.5, by volume) as mobile phase. UV analysis was conducted at 360.0 and 287.0 nm for colchicine and gallic acid, respectively [19].

Misra et al. [20] developed high-performance thin-layer chromatography for simultaneous determination of colchicine and gloriosine. Separation was conducted on TLC aluminum plates of silica gel 60 F₂₅₄ using developing system of chloroform: acetone: di-ethylamine (5.0:4.0:1.0, by volume) where densitometric quantification was achieved using 350.0 nm.

High Performance Liquid chromatography**Table 1: HPLC methods for COC determination and their applications**

Column	Mobile Phase	Flow rate (mL/min)	Detection	Application	Reference
C18 column HPLC	Methanol-acetonitrile (25.0:75.0, v/v)-pH (2.5-5.5)	3.0	350.0 nm	Stability study after hydrolysis and photodecomposition conditions	[21]
C8 column HPLC	Methanol-phosphate buffer (55.0: 45.0 v/v) (pH = 5.5)	1.0	254.0 nm	In pharmaceutical formulations	[22]
Stainless-steel Micropak MCH lo-pm column HPLC	Acetonitrile-water (50.0:50.0, v/v)	2.0	245.0 nm	Human plasma and urine	[23]
Zorbax-ODS C18 column HPLC	Methanol: water (60.0: 40.0, v/v)	1.0	243.0 nm	Crude drug and pharmaceutical dosage forms	[10]
C18 column HPLC	5.0 mM of l-pentanesulfonic acid-methanol-acetonitrile (60.0: 26.6: 13.4, by volume)- 0.1 M potassium hydroxide (pH= 6.0)	1.5	254.0 nm	Serum or urine	[24]
C18 column HPLC	Acetonitrile: 2.0 mM NH ₄ COOH, pH= 3.0 buffer (75.0: 25.0, v/v)	0.05	MS/MS	Biological fluids	[25]
C18 column HPLC	Gradient elution (0.5% formic acid-acetonitrile)	1.0	MS/MS	Sheep serum and milk	[26]
C18-Xterra column	Gradient elution (formate buffer (pH= 3.0)-acetonitrile)	0.2	MS/MS	Postmortem body Fluids	[27]
C18 Uptisphere column	Acetonitrile/2.0 mM NH ₄ COOH, pH= 3.8 buffer (50.0 :50.0, v/v)	0.2	MS/MS	Human plasma	[28]
Inertsil ODS-2	CH ₃ COONH ₄ 0.05 M: CH ₃ OH (48.0 :52.0, v/v)	1.0	245.0 nm	Pharmaceuticals and biological fluids	[29]
C18 column HPLC	Acetonitrile – 0.15% phosphoric acid solution (27.0:37.0, V/V)	1.0	350.0 nm	Mouse plasma	[30]
C18 column HPLC	Gradient elution (acetonitrile and 10.0 mmol L ⁻¹ of ammonium bicarbonate) pH =10.5	0.5	MS/MS	Blood and urine	[31]
Ultimate XB-C18 column HPLC	Gradient elution (0.2% aqueous formic acid- methanol)	0.6	MS	Human blood and gastric juice	[32]
C18 column HPLC	Acetonitrile–10.0 mM NaH ₂ PO ₄ , pH= 3.0 (35.0: 65.0, v/v)	1.0	245.0 nm	Pharmaceutical Formulations	[17]
C18 monolithic spin column HPLC	Gradient elution (water with 0.1 % acetic acid - acetonitrile)	0.4	MS/MS	Serum, urine, and plants	[33]
RP C18 column HPLC	Gradient elution (acetonitrile- water)	0.3	MS/MS	Herbal cosmetics	[34]
XBridge C18 column HPLC	Water: acetonitrile (75.0 :25.0, v/v)	1.0	MS	Gloriosa superba seeds	[35]
Eclipse XDB-C18 column HPLC	5.0 mM ammonium formate and 0.025% formic acid in acetonitrile (20.0 :80.0, v/v)	0.9	MS/MS	Rat plasma	[36]
An XBridge™ BEH C18 column	Gradient elution 0.01% (v/v) ammonia-methanol	0.35	MS/MS	Plasma and urine	[37]

solid phase extraction column and were detected from 210.0 nm to 400.0 nm [38].

Capillary Electrophoresis (CE)

Separation of colchicine and three toxic alkaloids namely, aconitine, nicotine, and strychnine was accomplished by capillary electrochromatography. Solvent mixture consisting of 2.0% NH₄OH, 20.0 % methanol, and 78.0 % ethyl acetate was utilized to remove the alkaloids from the

d. Stability indicating methods

Two stability-indicating methods (RP-TLC and HPLC method) have been reported for determination COL only under acidic conditions by the assist of a microwave. The first method was RP-TLC, where separation was achieved

using mobile phase of water: methanol: diethylamine (70.0: 30.0: 15.0, by volume) flow rate 1.0 mL/min with UV detection at 254.0 nm. The second method was HPLC, where separation was conducted using mobile phase of mixture of water (containing 0.02% diethyl amine): methanol: acetonitrile (50.0: 20.0: 30.0, by volume), flow rate 2.0 mL/min with UV detection at 254.0 nm [39]

Razeq *et al.* have tested COL stability under acidic, alkaline as well as oxidative conditions. COL was separated from its degradation product using RP-TLC, HPLC and spectrophotometric method. HP-TLC method was conducted on pre-coated silica gel 60 GF254 upon using Chloroform-methanol-conc ammonia (8.0: 2.0: 0.1 v/v/v) as a mobile phase and UV detection at 350.0 nm. HPLC method was achieved on kromasil C18 column and a mobile phase of methanol-ammonia (100.0: 1.5 v/v) with UV detection at 246.0 nm. spectrophotometric method was obtained using dual wavelength method at 245.0 nm and 261.0 nm and first derivative of ratio spectra at 302.4 nm [40]

Two stability-indicating methods namely, RP-TLC and HPLC method were developed for simultaneous determination of colchicine and probenecid where COL was tested under acidic, alkaline, oxidative, photolytic, and thermal degradation conditions. HP-TLC method was conducted on pre-coated silica gel 60 GF254 upon using ethyl acetate-methanol-33% ammonia (8.0: 1.0: 1.0, by volume) as mobile phase and UV detection at 254.0 nm. On the other hand, HPLC method was carried out on C18 column using phosphate buffer pH 5.0-acetonitrile (70.0: 30.0, v/v) as a mobile phase, flow rate 1.0 mL/min with UV detection at 254.0 nm [41]

stability indicating spectrophotometric methods have been developed for the concurrent determination of probenecid, colchicine and colchicine degradation product. These methods encompasses ratio difference, derivative ratio and mean centering of ratio spectra with linearity range 0.5–25.0 µg/mL and 1.0–13.0 µg/mL [42]

3. Conclusion

This review summarizes many analytical methods that have been reported in the literature for the identification of COC. The main goal of the review gathering is to collect and analyze as much data as possible on COC analytical methodologies. The results of the investigation indicate that only a small number of analytical procedures based on electrochemical and UV-Vis spectrophotometry are available, and that even fewer publications based on hyphenated methods are available.

Conflict of Interest

The Authors declare no conflict of interest.

References:

- S. C. Sweetman, *Martindale: The Complete Drug Reference. Drug Monographs*. Pharmaceutical press, 2011.
- S. L. Wallace, H. Robinson, A. T. Masi, J. L. Decker, D. J. Mccarty, and T. Yü, "Preliminary criteria for the classification of the acute arthritis of primary gout," *Arthritis Rheum*, vol. 20, no. 3, pp. 895–900, 1977.
- F. Salehzadeh, F. Pourfarzi, and S. Ataei, "The impact of colchicine on COVID-19 patients: a clinical trial study," *Mediterr J Rheumatol*, vol. 33, no. 2, p. 232, 2022.
- A. C. Moffat, M. D. Osselton, B. Widdop, and J. Watts, *Clarke's analysis of drugs and poisons*, vol. 3. Pharmaceutical press London, 2011.
- N. Dalbeth, T. J. Lauterio, and H. R. Wolfe, "Mechanism of action of colchicine in the treatment of gout," *Clin Ther*, vol. 36, no. 10, pp. 1465–1479, 2014.
- P. Galozzi, S. Bindoli, A. Doria, F. Oliviero, and P. Sfriso, "Autoinflammatory features in gouty arthritis," *J Clin Med*, vol. 10, no. 9, p. 1880, 2021.
- C. J. Toro-Huamanchumo *et al.*, "Efficacy of colchicine in the treatment of COVID-19 patients: A systematic review and meta-analysis," *J Clin Med*, vol. 11, no. 9, p. 2615, 2022.
- British pharmacopoeia, The Stationery Office, volume I, London, 2016.*
- US Pharmacopoeia 30; volume II. The United States Pharmacopoeial Convention, Rockville, USA, (2007).*
- T. M. Sarg, M. M. El-Domiaty, M. M. Bishr, O. M. Salama, and A. R. El-DomiatyGindy, "Thin-layer chromatographic scanner, spectrophotometric and high-performance liquid chromatographic methods for the determination of colchicine," *Analyst*, vol. 114, no. 5, pp. 575–578, 1989.
- T. Arai and T. Okuyama, "Fluorometric assay of tubulin-colchicine complex," *Anal Biochem*, vol. 69, no. 2, pp. 443–450, 1975.
- S. F. El-Malla, E. A. Elshenawy, S. F. Hammad, and F. R. Mansour, "N-Doped Carbon Dots as a Fluorescent Nanosensor for Determination of Colchicine Based on Inner Filter Effect," *J Fluoresc*, vol. 31, no. 3, pp. 675–684, 2021, doi: 10.1007/s10895-021-02698-0.
- H. Zhang, "Electrochemistry and voltammetric determination of colchicine using an acetylene black-dihexadecyl hydrogen phosphate composite film modified glassy carbon electrode," *Bioelectrochemistry*, vol. 68, no. 2, pp. 197–201, 2006.
- E. Bodoki, S. Laschi, I. Palchetti, R. Săndulescu, and M. Mascini, "Electrochemical behavior of colchicine using graphite-based screen-printed electrodes," *Talanta*, vol. 76, no. 2, pp. 288–294, 2008.
- M. Afzali, A. Mostafavi, and T. Shamspur, "Sensitive detection of colchicine at a glassy carbon electrode modified with magnetic ionic liquid/CuO nanoparticles/carbon nanofibers in pharmaceutical and plasma samples," *Journal of the Iranian Chemical Society*, vol. 17, no. 7, pp. 1753–1764, 2020.
- E. Bodoki, R. Oprean, L. Vlase, M. Tamas, and R. Sandulescu, "Fast determination of colchicine by TLC-densitometry from pharmaceuticals and vegetal extracts," *J Pharm Biomed Anal*, vol. 37, no. 5, pp. 971–977, 2005.
- G. M. Hadad, J. M. Badr, K. El-Nahriry, and H. A. Hassanean, "Validated HPLC and HPTLC methods for simultaneous determination of colchicine and khellin in pharmaceutical formulations," *J Chromatogr Sci*, vol. 51, no. 3, pp. 258–265, 2013.
- M. Fahim, M. Singh, Y. T. Kamal, H. M. Mukhtar, and S. Ahmad, "A high performance thin layer chromatographic method for the estimation of colchicine in different formulations," *J Pharm Bioallied Sci*, vol. 7, no. 4, p. 260, 2015.

19. A. Ali, A. Qadir, M. A. Khan, F. O. Al-Otaibi, S. Khan, and M. Z. Abdin, "A simple validated HPTLC method for simultaneous analysis of colchicine and gallic acid in polyherbal formulation: Habb-E-Irqun-Nisha," *Food Anal Methods*, vol. 10, no. 9, pp. 2934–2942, 2017.
20. A. Misra, B. Kumar, P. Shukla, and S. Srivastava, "Simultaneous HPTLC-UV quantification of colchicine and gloriosine alkaloids in the natural population of *Gloriosa superba* L., collected from Eastern Ghats of India for the identification of elite chemotypes," *J Liq Chromatogr Relat Technol*, vol. 43, no. 9–10, pp. 351–360, 2020.
21. E. Lacey and R. L. Brady, "Separation of colchicine and related hydrolysis and photodecomposition products by high-performance liquid chromatography, using copper ion complexation," *J Chromatogr A*, vol. 315, pp. 233–241, 1984.
22. R. D. Thompson, "Liquid chromatographic determination of colchicine in pharmaceuticals: collaborative study," *Journal of the Association of Official Analytical Chemists*, vol. 68, no. 5, pp. 1051–1055, 1985.
23. M. Lhermitte, J. L. Bernier, D. Mathieu, M. Mathieu-Nolf, F. Erb, and P. Roussel, "Colchicine quantitation by high-performance liquid chromatography in human plasma and urine," *J Chromatogr B Biomed Sci Appl*, vol. 342, pp. 416–423, 1985.
24. R. J. Ko, W. Y. Li, and R. T. Koda, "Determination of the antimitotic agents N-desacetylcolchicine, demecolcine and colchicine in serum and urine," *J Chromatogr B Biomed Sci Appl*, vol. 525, pp. 411–418, 1990.
25. A. Tracqui, P. Kintz, B. Ludes, C. Rouge, H. Douibi, and P. Mangin, "High-performance liquid chromatography coupled to ion spray mass spectrometry for the determination of colchicine at ppb levels in human biofluids," *J Chromatogr B Biomed Sci Appl*, vol. 675, no. 2, pp. 235–242, 1996.
26. G. Hamscher, B. Priess, H. Nau, and E. Panariti, "Determination of colchicine residues in sheep serum and milk using high-performance liquid chromatography combined with electrospray ionization ion trap tandem mass spectrometry," *Anal Chem*, vol. 77, no. 8, pp. 2421–2425, 2005.
27. M. Cheze, M. Deveaux, and G. Pepin, "Liquid chromatography-tandem mass spectrometry for the determination of colchicine in postmortem body fluids. Case report of two fatalities and review of the literature," *J Anal Toxicol*, vol. 30, no. 8, pp. 593–598, 2006.
28. E. Abe et al., "A novel LC-ESI-MS-MS method for sensitive quantification of colchicine in human plasma: application to two case reports," *J Anal Toxicol*, vol. 30, no. 3, pp. 210–215, 2006.
29. V. F. Samanidou, G. A. Sarantis, and I. N. Papadoyannis, "Development and validation of a rapid HPLC method for the direct determination of colchicine in pharmaceuticals and biological fluids," *J Liq Chromatogr Relat Technol*, vol. 29, no. 1, pp. 1–13, 2006.
30. Q. H. Chen, S. Hou, L. C. Gan, Y. B. Li, X. Song, and Z. Cai, "Determination of colchicine in mouse plasma by high performance liquid-chromatographic method with UV detection and its application to pharmacokinetic studies," *Yakugaku Zasshi*, vol. 127, no. 9, pp. 1485–1490, 2007.
31. P. Qiu, X. Chen, X. Chen, L. Lin, and C. Ai, "Simultaneous determination of five toxic alkaloids in body fluids by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry," *Journal of Chromatography B*, vol. 875, no. 2, pp. 471–477, 2008.
32. H. Wu, X. Xiong, X. Huang, Z. Zhu, F. Huang, and X. Lin, "Simultaneous determination of 17 toxic alkaloids in human fluids by liquid chromatography coupled with electrospray ionization tandem mass spectrometry," *J Liq Chromatogr Relat Technol*, vol. 36, no. 9, pp. 1149–1162, 2013.
33. T. Saito et al., "Identification and Quantification of Aconitines and Colchicine in Serum, Urine, and Plants using MonoSpin C 18 and LC-MSMS," *Chromatographia*, vol. 78, no. 15, pp. 1041–1048, 2015.
34. Z. Xun et al., "Simultaneous determination of eight alkaloids and oleandrin in herbal cosmetics by dispersive solid-phase extraction coupled with ultra high performance liquid chromatography and tandem mass spectrometry," *J Sep Sci*, vol. 40, no. 9, pp. 1966–1973, 2017.
35. A. Balkrishna et al., "Colchicine: Isolation, LC–MS QToF screening, and anticancer activity study of *Gloriosa superba* seeds," *Molecules*, vol. 24, no. 15, p. 2772, 2019.
36. B. B. Gabani et al., "Simultaneous determination of colchicine and febuxostat in rat plasma: Application in a rat pharmacokinetic study," *Biomedical Chromatography*, vol. 34, no. 11, p. e4939, 2020.
37. M. Qian, Z. Chen, X. Tao, F. Yao, and X. Xu, "In-syringe dispersive solid phase filter extraction cleanup followed by liquid chromatography-triple quadrupole mass spectrometry for fast determination of colchicine in plasma/urine," *J Pharm Biomed Anal*, vol. 228, p. 115317, 2023.
38. C. I. D. Newman, B. C. Giordano, C. L. Copper, and G. E. Collins, "Microchip micellar electrokinetic chromatography separation of alkaloids with UV-absorbance spectral detection," *Electrophoresis*, vol. 29, no. 4, pp. 803–810, 2008.
39. N. S. Abdelwahab, H. M. Hassan, and A. M. A. Magd, "Rapid microwave-assisted hydrolytic degradation of colchicine: In silico ADME/Tox profile, molecular docking, and development of innovative RP-Chromatographic methods," *Microchemical Journal*, vol. 152, p. 104419, 2020.
40. S. A. Abdel Razeq, I. A. Khalil, and S. A. Mohammed, "Stability-indicating chromatographic and UV spectrophotometric methods for determination of colchicine," *Journal of the Iranian Chemical Society*, vol. 17, pp. 2415–2427, 2020.
41. M. A. Tantawy, I. A. Wahba, S. S. Saad, and N. K. Ramadan, "Stability-indicating chromatographic methods for the simultaneous determination of probenecid and colchicine in their combined tablet," *J Chromatogr Sci*, vol. 59, no. 10, pp. 956–963, 2021.
42. M. A. Tantawy, I. A. Wahba, S. S. Saad, and N. K. Ramadan, "Smart spectrophotometric methods for stability assessment of two co-formulated antigout

drugs," *Spectrochim Acta A Mol Biomol Spectrosc*, vol.
273, p. 121062, 2022, doi:
<https://doi.org/10.1016/j.saa.2022.121062>.